GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Treasury Stock

GALDY (Galderma Group AG) Treasury Stock : $0 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Galderma Group AG's treasury stock for the quarter that ended in Jun. 2024 was $0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Galderma Group AG Treasury Stock Historical Data

The historical data trend for Galderma Group AG's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Treasury Stock Chart

Galderma Group AG Annual Data
Trend
Treasury Stock

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Treasury Stock - -

Galderma Group AG Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Galderma Group AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.